Navigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy
Abstract
Pityriasis rubra pilaris (PRP) is a rare and chronic dermatologic condition often misdiagnosed due to its clinical resemblance to psoriasis. It significantly impacts quality of life due to its clinical presentation and systemic discomfort. Conventional treatments, including retinoids, corticosteroids, and methotrexate, often yield suboptimal outcomes, particularly in refractory cases. Recently, biologic therapies have shown promise for PRP management. This case report describes the successful treatment of PRP with guselkumab. A 57-year-old male presented with an eight-year history of refractory papulosquamous disorder affecting 70% of his body surface area, initially diagnosed and treated as psoriasis. The patient had failed topical steroids, topical calcineurin inhibitors, sulfasalazine, and methotrexate. He had a past medical history of asthma treated with dupilumab. On skin exam, there were orange-red scaly plaques on the scalp, trunk, upper and lower extremities, buttocks, and genitals. Some of the plaques coalesced in areas to confluence, making PRP a presumptive diagnosis. Diagnosis was confirmed by three punch biopsies, and treatment with guselkumab 100mg subcutaneous injection was initiated. The patient noted improvement after the first loading dose and achieved complete skin clearance following the second dose four weeks later. At his one-year follow-up, he maintained full clearance while receiving guselkumab 100 mg subcutaneously every eight weeks. This case…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.